

REMARKS

With entry of the instant amendment, claims 42-46 are pending in the application.

New claims 43, 44, 45, and 46 recite a monoclonal antibody, a polyclonal antibody, a single chain Fv, and a humanized antibody, respectively. The claims add no new matter. Support can be found, *e.g.*, in the specification at page 21, line 1 through page 22, line 3.


The amendment to the specification at page 39, line 11, corrects an inadvertent error. The sentence on page 39, lines 10 and 11 refers to an "amino acid sequence"; however SEQ ID NO:1 and SEQ ID NO:7 are nucleic acid sequences. The amendment corrects the passage to refer to polypeptide sequences. Support for this amendment is found on page 39, lines 8 and 9, where the polypeptide sequences of the instant application are referred to as "SEQ ID NOS:2, 4, 6, or 8".

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer, Ph.D.
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:jml
60008123 v1